Eric Lefkofsky Tempus Unicorn Funding

Eric Lefkofsky is a Chicago based serial entrepreneur and philanthropist. He and Brad Keywell founded Tempus in 2015. Tempus is a technology company that has built an operating system to battle cancer. Tempus redefines genomic data in a clinical setting. The centralized system allows physicians to learn from previous cancer patients and find more effective treatment options for their patients.

The startup is expanding rapidly by adding 30 employees monthly to its existing 400 employees. Six months after Tempus raised a $70 million round; it raised $80 million in new funding on March. The funding brings the company’s total amount increased to $210 million with new investors including Kinship Trust Company and T. Rowe Price, along with existing investors New Enterprise Associates and Revolution Growth.

“Tempus was born out of frustration with a health care system that too often let powerful data and real-world evidence go to waste,” said Eric Lefkofsky, co-founder and CEO at Tempus. “Given the breadth and scale of our current data set, we’re in a unique position to help usher in an era of precision medicine to support patients battling diseases.”

Tempus takes on cancer by gathering information on the patient’s clinical and molecular data and creating a repository cancer patients’ data in structured form. They generate molecular data by sequencing patients’ DNA and RNA to uncover more personalized treatment. This would help prolong the lifespan of cancer patients.

The company works in collaboration with cancer research hospitals like the Mayo Clinic, Northwestern University, the University of Chicago, and the University of Michigan, the Cleveland Clinic, Duke University School of Medicine, the UC Davis Comprehensive Cancer Center and Knight Cancer Institute at the OHSU. It currently works with nearly half of all Academic Medical Centers in the United States.

“I think the traction we have had with everybody in the industry has been kind of amazing,” Lefkofsky said. “We’re in the midst of one of the most significant paradigm shifts of our time.”

https://www.bloomberg.com/research/stocks/people/person.asp?personId=166953&privcapId=82311805